Treatment with vandetanib significantly decreased the levels of p‐PI3K P85/P55 and the phosphorylation of AKT, MTOR, MEK1/2 and ERK1/2 and increased the phosphorylation of P38 in K562 tumor tissues (Fig. 5K,M,O). Here, MAP2K1 is linked to neoplasm.